CD86 Antibody [L10K15] | Primary Antibodies

Application: Reactivity: Mouse

Usage Information

Dilution
WB1:1000 IHC1:100 - 1:400

Application
WB, IHC

Reactivity
Mouse

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
60-85 kDa

Positive Control	Mouse spleen; Mouse liver; Mouse lung; CT26.WT syngeneic tumor; GL-261 syngeneic tumor; J774A.1 cells
Negative Control	Mouse spleen; Neuro-2a cells; BA/F3 cells

Datasheet & SDS

Biological Description

Specificity
CD86 Antibody [L10K15] detects endogenous levels of total CD86 protein.

Clone
L10K15

Synonym(s)
T-lymphocyte activation antigen CD86; Activation B7-2 antigen; Early T-cell costimulatory molecule 1 (ETC-1); CD86; Cd86

Background
CD86 (B7-2) is a type I membrane glycoprotein of the immunoglobulin superfamily, expressed on professional antigen-presenting cells, where it functions as a key costimulatory ligand for T cells through binding to the receptors CD28 and CTLA-4. CD86 has an extracellular region composed of two Ig-like domains, an N-terminal V-like domain and a C-terminal C-like domain, with the V-like domain alone sufficient to mediate high-efficiency binding to CTLA-4, highlighting its functionally dominant role in receptor engagement and signaling. CD86 is expressed at relatively high levels on resting monocytes and dendritic cells and is rapidly upregulated upon inflammatory or antigenic stimulation, enabling it to deliver early, potent costimulatory signals to naïve T cells via CD28. These signals are required, in addition to TCR engagement, for full T-cell activation, proliferation, cytokine production, and acquisition of effector functions. In contrast, CD86 interaction with CTLA-4 delivers inhibitory signals that downregulate T-cell responses, contributing to peripheral tolerance and limiting excessive or autoreactive immunity. Although both CD80 and CD86 can costimulate T cells, CD86 plays a key role in the initiation phase of T-cell responses in vivo, consistent with its rapid inducibility and efficient engagement of CD28. The balance between CD86–CD28–mediated activation and CD86–CTLA-4–mediated inhibition is therefore central to CD86's biological role in shaping the magnitude, timing, and quality of adaptive immune responses, with direct implications for autoimmunity, transplantation, and tumor immunity.

Background

CD86 (B7-2) is a type I membrane glycoprotein of the immunoglobulin superfamily, expressed on professional antigen-presenting cells, where it functions as a key costimulatory ligand for T cells through binding to the receptors CD28 and CTLA-4. CD86 has an extracellular region composed of two Ig-like domains, an N-terminal V-like domain and a C-terminal C-like domain, with the V-like domain alone sufficient to mediate high-efficiency binding to CTLA-4, highlighting its functionally dominant role in receptor engagement and signaling. CD86 is expressed at relatively high levels on resting monocytes and dendritic cells and is rapidly upregulated upon inflammatory or antigenic stimulation, enabling it to deliver early, potent costimulatory signals to naïve T cells via CD28. These signals are required, in addition to TCR engagement, for full T-cell activation, proliferation, cytokine production, and acquisition of effector functions. In contrast, CD86 interaction with CTLA-4 delivers inhibitory signals that downregulate T-cell responses, contributing to peripheral tolerance and limiting excessive or autoreactive immunity. Although both CD80 and CD86 can costimulate T cells, CD86 plays a key role in the initiation phase of T-cell responses in vivo, consistent with its rapid inducibility and efficient engagement of CD28. The balance between CD86–CD28–mediated activation and CD86–CTLA-4–mediated inhibition is therefore central to CD86's biological role in shaping the magnitude, timing, and quality of adaptive immune responses, with direct implications for autoimmunity, transplantation, and tumor immunity.

References
https://pubmed.ncbi.nlm.nih.gov/7535614/ https://pubmed.ncbi.nlm.nih.gov/8609386/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%